Bromazolam - Revision history

MDElliottMD: Category taxonomy ship: retag Research Materials -> Research chemicals, Sedative-Hypnotics -> Sedative-hypnotics

2026-05-22T00:35:46Z

Category taxonomy ship: retag Research Materials -> Research chemicals, Sedative-Hypnotics -> Sedative-hypnotics

← Older revision		Revision as of 00:35, 22 May 2026
Line 43:		Line 43:


	[[Category:Research ~~Materials~~]]		[[Category:Research chemicals]]
	[[Category:Benzodiazepines]]		[[Category:Benzodiazepines]]
	[[Category:Triazolobenzodiazepines]]		[[Category:Triazolobenzodiazepines]]
	[[Category:GABAA Positive Allosteric Modulators (General)]]		[[Category:GABAA Positive Allosteric Modulators (General)]]
	[[Category:GABAergics]]		[[Category:GABAergics]]
	[[Category:Sedative-~~Hypnotics~~]]		[[Category:Sedative-hypnotics]]

MDElliottMD: Tier 2 taxonomy consolidation: add Category:Sedative-Hypnotics; remove retired Category:Anxiolytics & Sedative-Hypnotics

2026-05-21T17:44:41Z

Tier 2 taxonomy consolidation: add Category:Sedative-Hypnotics; remove retired Category:Anxiolytics & Sedative-Hypnotics

← Older revision		Revision as of 17:44, 21 May 2026
Line 48:		Line 48:
	[[Category:GABAA Positive Allosteric Modulators (General)]]		[[Category:GABAA Positive Allosteric Modulators (General)]]
	[[Category:GABAergics]]		[[Category:GABAergics]]
	[[Category:~~Anxiolytics &~~ Sedative-Hypnotics]]		[[Category:Sedative-Hypnotics]]

MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

2026-05-19T03:16:05Z

Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

MDElliottMD: Sweep: "indications" -> "problems" sitewide terminology update (preserves MedTemplate param name)

2026-05-19T01:37:45Z

Sweep: "indications" -> "problems" sitewide terminology update (preserves MedTemplate param name)

← Older revision		Revision as of 01:37, 19 May 2026
Line 5:		Line 5:
	\| classes = Designer benzodiazepine, Triazolobenzodiazepine, Sedative-Hypnotic, Research material		\| classes = Designer benzodiazepine, Triazolobenzodiazepine, Sedative-Hypnotic, Research material
	\| mechanism = Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects.		\| mechanism = Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects.
	\| uses = No approved medical ~~indication~~. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies.		\| uses = No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies.
	\| starting_dose = No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam).		\| starting_dose = No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam).
	\| preparations = Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists.		\| preparations = Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists.

Maintenance script: Terminology: medicine → med (shorter form per user preference)

2026-05-16T02:42:47Z

Terminology: medicine → med (shorter form per user preference)

← Older revision		Revision as of 02:42, 16 May 2026
Line 15:		Line 15:
	\| bioavailability = Not formally characterized in humans.		\| bioavailability = Not formally characterized in humans.
	\| pregnancy = Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data — assume worst-case.		\| pregnancy = Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data — assume worst-case.
	\| legal = First synthesized by Upjohn in 1976; never marketed. Schedule I in several U.S. states (e.g., Virginia, Florida, Mississippi, Alabama); federally unscheduled in the U.S. as of mid-2020s but DEA has listed it as a ~~medicine~~ of concern. Class C in the UK (generic benzodiazepine controls). Controlled in Sweden, Germany (NpSG), Switzerland, and Canada.		\| legal = First synthesized by Upjohn in 1976; never marketed. Schedule I in several U.S. states (e.g., Virginia, Florida, Mississippi, Alabama); federally unscheduled in the U.S. as of mid-2020s but DEA has listed it as a med of concern. Class C in the UK (generic benzodiazepine controls). Controlled in Sweden, Germany (NpSG), Switzerland, and Canada.
	\| intro = '''Bromazolam''' is a triazolobenzodiazepine first synthesized by Upjohn in 1976 and never developed clinically. It emerged on the research-chemical market around 2016 and, beginning around 2021–2022, became one of the most commonly encountered designer benzodiazepines in North America — notably as an adulterant in the illicit opioid supply alongside fentanyl and, often, xylazine. Pharmacologically and structurally it is the bromine analog of alprazolam, with comparable potency and a similar (or somewhat longer) duration of action.		\| intro = '''Bromazolam''' is a triazolobenzodiazepine first synthesized by Upjohn in 1976 and never developed clinically. It emerged on the research-chemical market around 2016 and, beginning around 2021–2022, became one of the most commonly encountered designer benzodiazepines in North America — notably as an adulterant in the illicit opioid supply alongside fentanyl and, often, xylazine. Pharmacologically and structurally it is the bromine analog of alprazolam, with comparable potency and a similar (or somewhat longer) duration of action.
	\| pharmacokinetics = Lipophilic; orally bioavailable; hepatic metabolism (CYP3A4 predominantly) with hydroxylated metabolites. Half-life appears longer than alprazolam, with case reports of detection in blood/urine for days after a single exposure. Standard benzodiazepine immunoassay screens frequently '''miss''' bromazolam — confirmatory LC-MS/MS is required for reliable detection.		\| pharmacokinetics = Lipophilic; orally bioavailable; hepatic metabolism (CYP3A4 predominantly) with hydroxylated metabolites. Half-life appears longer than alprazolam, with case reports of detection in blood/urine for days after a single exposure. Standard benzodiazepine immunoassay screens frequently '''miss''' bromazolam — confirmatory LC-MS/MS is required for reliable detection.
Line 39:		Line 39:
	* Papsun DM, et al. Forensic toxicology of bromazolam. ''J Anal Toxicol'' 2022.		* Papsun DM, et al. Forensic toxicology of bromazolam. ''J Anal Toxicol'' 2022.
	* CFSRE / NPS Discovery. Bromazolam emergence reports, 2021–2024.		* CFSRE / NPS Discovery. Bromazolam emergence reports, 2021–2024.
	* Health Canada / CCENDU bulletins on designer benzodiazepines in the unregulated ~~medicine~~ supply.		* Health Canada / CCENDU bulletins on designer benzodiazepines in the unregulated med supply.
	}}		}}

Maintenance script: Revert Bromazolam L38: 'Drug' is a proper noun in DEA citation

2026-05-16T02:42:45Z

Revert Bromazolam L38: 'Drug' is a proper noun in DEA citation

← Older revision		Revision as of 02:42, 16 May 2026
Line 36:		Line 36:
	\| seealso = [[Alprazolam]], [[Clonazolam]], [[Flualprazolam]], [[Etizolam]], [[Flumazenil]], [[Fentanyl]], [[Xylazine]], [[Naloxone]]		\| seealso = [[Alprazolam]], [[Clonazolam]], [[Flualprazolam]], [[Etizolam]], [[Flumazenil]], [[Fentanyl]], [[Xylazine]], [[Naloxone]]
	\| references =		\| references =
	* DEA Diversion. ''Bromazolam.'' ~~Medicine~~ & Chemical Evaluation Section, 2023.		* DEA Diversion. ''Bromazolam.'' Drug & Chemical Evaluation Section, 2023.
	* Papsun DM, et al. Forensic toxicology of bromazolam. ''J Anal Toxicol'' 2022.		* Papsun DM, et al. Forensic toxicology of bromazolam. ''J Anal Toxicol'' 2022.
	* CFSRE / NPS Discovery. Bromazolam emergence reports, 2021–2024.		* CFSRE / NPS Discovery. Bromazolam emergence reports, 2021–2024.

Maintenance script: Terminology sweep (site-wide): drug/medication → medicine

2026-05-16T02:30:58Z

Terminology sweep (site-wide): drug/medication → medicine

← Older revision		Revision as of 02:30, 16 May 2026
Line 15:		Line 15:
	\| bioavailability = Not formally characterized in humans.		\| bioavailability = Not formally characterized in humans.
	\| pregnancy = Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data — assume worst-case.		\| pregnancy = Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data — assume worst-case.
	\| legal = First synthesized by Upjohn in 1976; never marketed. Schedule I in several U.S. states (e.g., Virginia, Florida, Mississippi, Alabama); federally unscheduled in the U.S. as of mid-2020s but DEA has listed it as a ~~drug~~ of concern. Class C in the UK (generic benzodiazepine controls). Controlled in Sweden, Germany (NpSG), Switzerland, and Canada.		\| legal = First synthesized by Upjohn in 1976; never marketed. Schedule I in several U.S. states (e.g., Virginia, Florida, Mississippi, Alabama); federally unscheduled in the U.S. as of mid-2020s but DEA has listed it as a medicine of concern. Class C in the UK (generic benzodiazepine controls). Controlled in Sweden, Germany (NpSG), Switzerland, and Canada.
	\| intro = '''Bromazolam''' is a triazolobenzodiazepine first synthesized by Upjohn in 1976 and never developed clinically. It emerged on the research-chemical market around 2016 and, beginning around 2021–2022, became one of the most commonly encountered designer benzodiazepines in North America — notably as an adulterant in the illicit opioid supply alongside fentanyl and, often, xylazine. Pharmacologically and structurally it is the bromine analog of alprazolam, with comparable potency and a similar (or somewhat longer) duration of action.		\| intro = '''Bromazolam''' is a triazolobenzodiazepine first synthesized by Upjohn in 1976 and never developed clinically. It emerged on the research-chemical market around 2016 and, beginning around 2021–2022, became one of the most commonly encountered designer benzodiazepines in North America — notably as an adulterant in the illicit opioid supply alongside fentanyl and, often, xylazine. Pharmacologically and structurally it is the bromine analog of alprazolam, with comparable potency and a similar (or somewhat longer) duration of action.
	\| pharmacokinetics = Lipophilic; orally bioavailable; hepatic metabolism (CYP3A4 predominantly) with hydroxylated metabolites. Half-life appears longer than alprazolam, with case reports of detection in blood/urine for days after a single exposure. Standard benzodiazepine immunoassay screens frequently '''miss''' bromazolam — confirmatory LC-MS/MS is required for reliable detection.		\| pharmacokinetics = Lipophilic; orally bioavailable; hepatic metabolism (CYP3A4 predominantly) with hydroxylated metabolites. Half-life appears longer than alprazolam, with case reports of detection in blood/urine for days after a single exposure. Standard benzodiazepine immunoassay screens frequently '''miss''' bromazolam — confirmatory LC-MS/MS is required for reliable detection.
Line 36:		Line 36:
	\| seealso = [[Alprazolam]], [[Clonazolam]], [[Flualprazolam]], [[Etizolam]], [[Flumazenil]], [[Fentanyl]], [[Xylazine]], [[Naloxone]]		\| seealso = [[Alprazolam]], [[Clonazolam]], [[Flualprazolam]], [[Etizolam]], [[Flumazenil]], [[Fentanyl]], [[Xylazine]], [[Naloxone]]
	\| references =		\| references =
	* DEA Diversion. ''Bromazolam.'' ~~Drug~~ & Chemical Evaluation Section, 2023.		* DEA Diversion. ''Bromazolam.'' Medicine & Chemical Evaluation Section, 2023.
	* Papsun DM, et al. Forensic toxicology of bromazolam. ''J Anal Toxicol'' 2022.		* Papsun DM, et al. Forensic toxicology of bromazolam. ''J Anal Toxicol'' 2022.
	* CFSRE / NPS Discovery. Bromazolam emergence reports, 2021–2024.		* CFSRE / NPS Discovery. Bromazolam emergence reports, 2021–2024.
	* Health Canada / CCENDU bulletins on designer benzodiazepines in the unregulated ~~drug~~ supply.		* Health Canada / CCENDU bulletins on designer benzodiazepines in the unregulated medicine supply.
	}}		}}

Maintenance script: Create Bromazolam page (designer benzodiazepine; harm-reduction)

2026-05-15T18:46:13Z

Create Bromazolam page (designer benzodiazepine; harm-reduction)

New page

{{MedTemplate
| generic = Bromazolam
| brand = (none — never marketed)
| structure = Triazolobenzodiazepine; 8-bromo analog of alprazolam (bromine in place of the chloro substituent at the 8-position).
| classes = Designer benzodiazepine, Triazolobenzodiazepine, Sedative-Hypnotic, Research material
| mechanism = Positive allosteric modulator of the GABAA receptor at the benzodiazepine binding site; increases frequency of Cl− channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects.
| uses = No approved medical indication. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies.
| starting_dose = No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam).
| preparations = Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists.
| fda_max = N/A (never approved)
| routes = Oral, sublingual, intranasal; rectal and IV reported.
| onset = ~20–40 min PO; faster sublingual/intranasal.
| duration = 6–10 h subjective; full pharmacologic effect considerably longer.
| halflife = Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect.
| bioavailability = Not formally characterized in humans.
| pregnancy = Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data — assume worst-case.
| legal = First synthesized by Upjohn in 1976; never marketed. Schedule I in several U.S. states (e.g., Virginia, Florida, Mississippi, Alabama); federally unscheduled in the U.S. as of mid-2020s but DEA has listed it as a drug of concern. Class C in the UK (generic benzodiazepine controls). Controlled in Sweden, Germany (NpSG), Switzerland, and Canada.
| intro = '''Bromazolam''' is a triazolobenzodiazepine first synthesized by Upjohn in 1976 and never developed clinically. It emerged on the research-chemical market around 2016 and, beginning around 2021–2022, became one of the most commonly encountered designer benzodiazepines in North America — notably as an adulterant in the illicit opioid supply alongside fentanyl and, often, xylazine. Pharmacologically and structurally it is the bromine analog of alprazolam, with comparable potency and a similar (or somewhat longer) duration of action.
| pharmacokinetics = Lipophilic; orally bioavailable; hepatic metabolism (CYP3A4 predominantly) with hydroxylated metabolites. Half-life appears longer than alprazolam, with case reports of detection in blood/urine for days after a single exposure. Standard benzodiazepine immunoassay screens frequently '''miss''' bromazolam — confirmatory LC-MS/MS is required for reliable detection.
| pharmacodynamics = Non-selective positive allosteric modulator at the benzodiazepine site of GABAA receptors containing α1, α2, α3, or α5 subunits with a γ subunit. Like alprazolam, clinically displays anxiolytic, hypnotic, anticonvulsant, amnestic, and muscle-relaxant effects with significant abuse liability. Respiratory depression at high doses is modest in isolation but markedly synergized by opioids, alcohol, and other CNS depressants — the dominant mechanism of bromazolam-associated mortality.
| indications = None approved. Has no recognized medical role.
| dosing = No therapeutic dosing. Harm-reduction note: because of inconsistent tablet purity and frequent fentanyl co-contamination, '''any''' illicit "benzo" tablet should be assumed to potentially contain bromazolam, fentanyl, or both.
| effects = Sedation, anxiolysis, anterograde amnesia, ataxia, slurred speech, disinhibition, prolonged blackouts. At high dose or in combination: severe sedation, respiratory depression, coma. Paradoxical agitation/aggression occasionally reported. Withdrawal mirrors other high-potency benzos: anxiety, insomnia, autonomic hyperactivity, seizures, delirium — and can be life-threatening, often more protracted than alprazolam withdrawal owing to the longer half-life.
| interactions = <pharmaInteractions/>

* '''Opioids''' (fentanyl, heroin, methadone, buprenorphine): profound additive respiratory depression — primary mechanism of bromazolam-associated overdose death.
* '''Alcohol, GHB, barbiturates, gabapentinoids''': additive CNS/respiratory depression.
* '''Xylazine''': frequently co-encountered in illicit opioid supply ("tranq dope"); compounds sedation and complicates resuscitation (xylazine is not reversed by naloxone).
* '''CYP3A4 inhibitors''' (azoles, macrolides, ritonavir, grapefruit): prolong/intensify effect.
* '''CYP3A4 inducers''' (rifampin, carbamazepine, phenytoin, St John's wort): may reduce levels.
* '''Flumazenil''' reverses GABAA effects but is rarely used in mixed-overdose / chronic-benzo contexts due to seizure risk.
| pregnancy_details = Avoid in pregnancy and lactation. Class data extrapolated from clinical benzodiazepines; designer status means no formal safety data.
| monitoring = In suspected overdose: airway, respiratory rate, oxygen saturation, mental status. Standard urine benzodiazepine immunoassay is '''insensitive''' to bromazolam — request specific LC-MS/MS confirmation. ECG and electrolytes if mixed overdose suspected.
| counseling = Patients should be counseled that illicit "Xanax bars" or designer benzodiazepine tablets are frequently bromazolam and/or fentanyl. Never combine with opioids or alcohol. Withdrawal requires medically supervised taper — do not stop abruptly after sustained use. Carry naloxone if any opioid co-use is plausible (naloxone does '''not''' reverse bromazolam itself but reverses concurrent opioid depression).
| anecdotes =
| seealso = [[Alprazolam]], [[Clonazolam]], [[Flualprazolam]], [[Etizolam]], [[Flumazenil]], [[Fentanyl]], [[Xylazine]], [[Naloxone]]
| references =
* DEA Diversion. ''Bromazolam.'' Drug & Chemical Evaluation Section, 2023.
* Papsun DM, et al. Forensic toxicology of bromazolam. ''J Anal Toxicol'' 2022.
* CFSRE / NPS Discovery. Bromazolam emergence reports, 2021–2024.
* Health Canada / CCENDU bulletins on designer benzodiazepines in the unregulated drug supply.
}}

[[Category:Research Materials]]
[[Category:Benzodiazepines]]
[[Category:Triazolobenzodiazepines]]
[[Category:GABAA Positive Allosteric Modulators (General)]]
[[Category:GABAergics]]
[[Category:Anxiolytics & Sedative-Hypnotics]]

← Older revision		Revision as of 03:16, 19 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	\| generic = Bromazolam		\| generic = Bromazolam
	\| brand = (none — never marketed)		\| brand = (none, never marketed)
	\| structure = Triazolobenzodiazepine; 8-bromo analog of alprazolam (bromine in place of the chloro substituent at the 8-position).		\| structure = Triazolobenzodiazepine; 8-bromo analog of alprazolam (bromine in place of the chloro substituent at the 8-position).
	\| classes = Designer benzodiazepine, Triazolobenzodiazepine, Sedative-Hypnotic, Research material		\| classes = Designer benzodiazepine, Triazolobenzodiazepine, Sedative-Hypnotic, Research material
Line 14:		Line 14:
	\| halflife = Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect.		\| halflife = Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect.
	\| bioavailability = Not formally characterized in humans.		\| bioavailability = Not formally characterized in humans.
	\| pregnancy = Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data — assume worst-case.		\| pregnancy = Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case.
	\| legal = First synthesized by Upjohn in 1976; never marketed. Schedule I in several U.S. states (e.g., Virginia, Florida, Mississippi, Alabama); federally unscheduled in the U.S. as of mid-2020s but DEA has listed it as a med of concern. Class C in the UK (generic benzodiazepine controls). Controlled in Sweden, Germany (NpSG), Switzerland, and Canada.		\| legal = First synthesized by Upjohn in 1976; never marketed. Schedule I in several U.S. states (e.g., Virginia, Florida, Mississippi, Alabama); federally unscheduled in the U.S. as of mid-2020s but DEA has listed it as a med of concern. Class C in the UK (generic benzodiazepine controls). Controlled in Sweden, Germany (NpSG), Switzerland, and Canada.
	\| intro = '''Bromazolam''' is a triazolobenzodiazepine first synthesized by Upjohn in 1976 and never developed clinically. It emerged on the research-chemical market around 2016 and, beginning around 2021–2022, became one of the most commonly encountered designer benzodiazepines in North America — notably as an adulterant in the illicit opioid supply alongside fentanyl and, often, xylazine. Pharmacologically and structurally it is the bromine analog of alprazolam, with comparable potency and a similar (or somewhat longer) duration of action.		\| intro = '''Bromazolam''' is a triazolobenzodiazepine first synthesized by Upjohn in 1976 and never developed clinically. It emerged on the research-chemical market around 2016 and, beginning around 2021–2022, became one of the most commonly encountered designer benzodiazepines in North America, notably as an adulterant in the illicit opioid supply alongside fentanyl and, often, xylazine. Pharmacologically and structurally it is the bromine analog of alprazolam, with comparable potency and a similar (or somewhat longer) duration of action.
	\| pharmacokinetics = Lipophilic; orally bioavailable; hepatic metabolism (CYP3A4 predominantly) with hydroxylated metabolites. Half-life appears longer than alprazolam, with case reports of detection in blood/urine for days after a single exposure. Standard benzodiazepine immunoassay screens frequently '''miss''' bromazolam — confirmatory LC-MS/MS is required for reliable detection.		\| pharmacokinetics = Lipophilic; orally bioavailable; hepatic metabolism (CYP3A4 predominantly) with hydroxylated metabolites. Half-life appears longer than alprazolam, with case reports of detection in blood/urine for days after a single exposure. Standard benzodiazepine immunoassay screens frequently '''miss''' bromazolam, confirmatory LC-MS/MS is required for reliable detection.
	\| pharmacodynamics = Non-selective positive allosteric modulator at the benzodiazepine site of GABA<sub>A</sub> receptors containing α1, α2, α3, or α5 subunits with a γ subunit. Like alprazolam, clinically displays anxiolytic, hypnotic, anticonvulsant, amnestic, and muscle-relaxant effects with significant abuse liability. Respiratory depression at high doses is modest in isolation but markedly synergized by opioids, alcohol, and other CNS depressants — the dominant mechanism of bromazolam-associated mortality.		\| pharmacodynamics = Non-selective positive allosteric modulator at the benzodiazepine site of GABA<sub>A</sub> receptors containing α1, α2, α3, or α5 subunits with a γ subunit. Like alprazolam, clinically displays anxiolytic, hypnotic, anticonvulsant, amnestic, and muscle-relaxant effects with significant abuse liability. Respiratory depression at high doses is modest in isolation but markedly synergized by opioids, alcohol, and other CNS depressants, the dominant mechanism of bromazolam-associated mortality.
	\| indications = None approved. Has no recognized medical role.		\| indications = None approved. Has no recognized medical role.
	\| dosing = No therapeutic dosing. Harm-reduction note: because of inconsistent tablet purity and frequent fentanyl co-contamination, '''any''' illicit "benzo" tablet should be assumed to potentially contain bromazolam, fentanyl, or both.		\| dosing = No therapeutic dosing. Harm-reduction note: because of inconsistent tablet purity and frequent fentanyl co-contamination, '''any''' illicit "benzo" tablet should be assumed to potentially contain bromazolam, fentanyl, or both.
	\| effects = Sedation, anxiolysis, anterograde amnesia, ataxia, slurred speech, disinhibition, prolonged blackouts. At high dose or in combination: severe sedation, respiratory depression, coma. Paradoxical agitation/aggression occasionally reported. Withdrawal mirrors other high-potency benzos: anxiety, insomnia, autonomic hyperactivity, seizures, delirium — and can be life-threatening, often more protracted than alprazolam withdrawal owing to the longer half-life.		\| effects = Sedation, anxiolysis, anterograde amnesia, ataxia, slurred speech, disinhibition, prolonged blackouts. At high dose or in combination: severe sedation, respiratory depression, coma. Paradoxical agitation/aggression occasionally reported. Withdrawal mirrors other high-potency benzos: anxiety, insomnia, autonomic hyperactivity, seizures, delirium, and can be life-threatening, often more protracted than alprazolam withdrawal owing to the longer half-life.
	\| interactions = <pharmaInteractions/>		\| interactions = <pharmaInteractions/>

	* '''Opioids''' (fentanyl, heroin, methadone, buprenorphine): profound additive respiratory depression — primary mechanism of bromazolam-associated overdose death.		* '''Opioids''' (fentanyl, heroin, methadone, buprenorphine): profound additive respiratory depression, primary mechanism of bromazolam-associated overdose death.
	* '''Alcohol, GHB, barbiturates, gabapentinoids''': additive CNS/respiratory depression.		* '''Alcohol, GHB, barbiturates, gabapentinoids''': additive CNS/respiratory depression.
	* '''Xylazine''': frequently co-encountered in illicit opioid supply ("tranq dope"); compounds sedation and complicates resuscitation (xylazine is not reversed by naloxone).		* '''Xylazine''': frequently co-encountered in illicit opioid supply ("tranq dope"); compounds sedation and complicates resuscitation (xylazine is not reversed by naloxone).
Line 31:		Line 31:
	* '''Flumazenil''' reverses GABA<sub>A</sub> effects but is rarely used in mixed-overdose / chronic-benzo contexts due to seizure risk.		* '''Flumazenil''' reverses GABA<sub>A</sub> effects but is rarely used in mixed-overdose / chronic-benzo contexts due to seizure risk.
	\| pregnancy_details = Avoid in pregnancy and lactation. Class data extrapolated from clinical benzodiazepines; designer status means no formal safety data.		\| pregnancy_details = Avoid in pregnancy and lactation. Class data extrapolated from clinical benzodiazepines; designer status means no formal safety data.
	\| monitoring = In suspected overdose: airway, respiratory rate, oxygen saturation, mental status. Standard urine benzodiazepine immunoassay is '''insensitive''' to bromazolam — request specific LC-MS/MS confirmation. ECG and electrolytes if mixed overdose suspected.		\| monitoring = In suspected overdose: airway, respiratory rate, oxygen saturation, mental status. Standard urine benzodiazepine immunoassay is '''insensitive''' to bromazolam, request specific LC-MS/MS confirmation. ECG and electrolytes if mixed overdose suspected.
	\| counseling = Patients should be counseled that illicit "Xanax bars" or designer benzodiazepine tablets are frequently bromazolam and/or fentanyl. Never combine with opioids or alcohol. Withdrawal requires medically supervised taper — do not stop abruptly after sustained use. Carry naloxone if any opioid co-use is plausible (naloxone does '''not''' reverse bromazolam itself but reverses concurrent opioid depression).		\| counseling = Patients should be counseled that illicit "Xanax bars" or designer benzodiazepine tablets are frequently bromazolam and/or fentanyl. Never combine with opioids or alcohol. Withdrawal requires medically supervised taper, do not stop abruptly after sustained use. Carry naloxone if any opioid co-use is plausible (naloxone does '''not''' reverse bromazolam itself but reverses concurrent opioid depression).
	\| anecdotes =		\| anecdotes =
	\| seealso = [[Alprazolam]], [[Clonazolam]], [[Flualprazolam]], [[Etizolam]], [[Flumazenil]], [[Fentanyl]], [[Xylazine]], [[Naloxone]]		\| seealso = [[Alprazolam]], [[Clonazolam]], [[Flualprazolam]], [[Etizolam]], [[Flumazenil]], [[Fentanyl]], [[Xylazine]], [[Naloxone]]